Last reviewed · How we verify
Ceftriaxone plus vancomycin
At a glance
| Generic name | Ceftriaxone plus vancomycin |
|---|---|
| Sponsor | Forest Laboratories |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Early Antibiotics After Aspiration in ICU Patients (PHASE4)
- Antibiotic Concentrations Among Critically Ill Patients
- Efficacy of LiveSpo Navax in Supportive Treatment of Pneumonia in Children With RSV and Bacterial Co-infections (NA)
- Parenteral Versus Combined Parenteral With Vancomycin-soaked Graft in ACL Reconstruction (NA)
- Vancomycin and Tobramycin Powder Use in Acute Open Fractures (EARLY_PHASE1)
- Effects of Probiotic in Treatment of Persistent Diarrhea in Children (NA)
- Postoperative Antibiotic Management Duration Following Surgery for Intravenous Drug Abuse (IVDA) Endocarditis (OPTIMAL) (PHASE4)
- Ceftobiprole in the Treatment of Pediatric Patients With Pneumonia (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |